Abstract
The slow development of major advances in drug discovery for the treatment of Mycobacterium tuberculosis (Mtb) infection have led to a compelling need for evaluation of more effective drug therapies against tuberculosis. New classes of drugs are constantly being evaluated for anti-mycobacterial activity with currently a very limited number of new drugs approved for TB treatment. Minor Groove Binders (MGBs) have previously revealed promising anti-microbial activity against various infectious agents; however have not yet been screened against Mtb.
Original language | English |
---|---|
Pages (from-to) | 3334–3341 |
Number of pages | 8 |
Journal | Journal of Antimicrobial Chemotherapy |
Volume | 72 |
Issue number | 12 |
Early online date | 18 Sept 2017 |
DOIs | |
Publication status | Published - 1 Dec 2017 |
Keywords
- drug discovery
- minor groove binder
- tuberculosis
Fingerprint
Dive into the research topics of 'Evaluation of minor groove binders (MGBs) as novel anti-mycobacterial agents, and the effect of using non-ionic surfactant vesicles as a delivery system to improve their efficacy'. Together they form a unique fingerprint.Profiles
-
Katharine Carter
- Strathclyde Institute Of Pharmacy And Biomedical Sciences - Senior Lecturer
Person: Academic